2063 results about "On cells" patented technology

A method of determining information about cell viability and other characteristics relating to cell membrane permeability is disclosed. The method involves determining the effect of a cell on current flow and relating that effect to a known standard which standard may be a known healthy cell and thereby deducing the viability of the cell being tested. The cells being tested can be subjected to different environmental conditions such as surrounding chemicals, temperature, pH and pressure to determine the effects of such conditions on cell viability and/or cell permeability. The cell being tested can be in a cell suspension, grown on s ubstarte, in tissue in vitro or in tissue in vivo. The method provides substantially instantaneous results and need not include the use of dyes or other markers.

A Common radio resource management method is performed in a mobile radio communication network employing different radio access technologies that overlap over a geographic area subdivided into cells belonging to the domains of respective controllers which are connected to each other in overlapping or adjacent domains and to a core network by means of relevant interfaces. The controllers calculate new traffic-related Information Elements to be exchanged over the existing interfaces to the aim of planning handovers and/or cell reselections towards adjacent cells either of the same or different RAT. Cell capabilities and mobile terminal capabilitiess being also specified by respective IEs. Diversely from the conventional traffic-related IEs based on Cell Load parameters or Free Capacity, the new IEs include indications of the “availability” of bearer services in the cell in terms of maximum bitrate, either guaranteed or not guaranteed, that can currently be allowed to each bearer service.

The invention relates, in part, to the improved analysis of carbohydrates. In particular, the invention relates to the analysis of carbohydrates, such as N-glycans and O-glycans found on proteins and saccharides attached to lipids. Improved methods, therefore, for the study of glycosylation patterns on cells, tissue and body fluids are also provided. Information from the analysis of glycans, such as the glycosylation patterns on cells, tissues and in body fluids, can be used in diagnostic and treatment methods as well as for facilitating the study of the effects of glycosylation/altered glycosylation. Such methods are also provided. Methods are further provided to assess production processes, to assess the purity of samples containing glycoconjugates, and to select glycoconjugates with the desired glycosylation.

The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.

A method is disclosed that a Mobile Station MS performs at switch-on to search the most favorable target cell in UMTS systems like the 3GPP CDMA—LCR (Low Chip Rate) option at 1.28 Mcps—TDD (Time Division Duplex) mode and the equivalent TD-SCDMA (Time Division—Synchronous CDMA). Signal at the MS antenna is the sum of different RF downlink frames coming from different carriers in the assigned frequency ranges. A DL synchronization timeslot and a BCCH TS0 are both transmitted with full power in the frames, the first one includes one out of 32 SYNC codes assigned on cell basis. Following a conventional approach the absence of a common downlink pilot and without prior knowledge of the used frequencies would force the MS, for all the frequencies of the channel raster stored in the SIM card, the correlation of the received frame with all the 32 SYNCs stored in the MS, in order to detect the BSIC of a cell to which associate the power measures. Following the two-step method of the invention the power measures are performed in two-step scan of the PLMN band without interleaved correlation steps; once a final frequency is selected the respective frame is the only correlated one. At least one frame duration about 5 ms long of the whole 15 MHz bandwidth is acquired, IF converted, A/D converted and the digital set is stored. A rough scan is performed multiplying the digital set by a digital IF tuned in steps wide as the channel band (1.6 MHz) along the 15 MHz band, and filtering the baseband signal with a Root Raise Cosine low-pass filter. The 5 ms baseband signal is subdivided into 15 blocks of half timeslot (337.5 μs) and the power of each block is measured. The power of the strongest block indicates the priority of the respective frequency. The strongest power values are put in a Spectral Table together with respective frame load indicators. The load indicator is the percentage of timeslots in a frame almost equally loaded as the strongest block. The three strongest frequencies are selected for the successive scan. The second step search is performed like the first one but the IF steps are now 200 kHz wide and cover the only 1.6 MHz spectrum around a selected frequency. A final frequency is selected for the successive correlation step. Then the frequency error of the MS reference oscillator is corrected with data-aided techniques and a calibration value stored for successive connections (FIG. 9).

The invention relates, in part, to the improved analysis of carbohydrates. In particular, the invention relates to the analysis of carbohydrates, such as N-glycans and O-glycans found on proteins. Improved methods, therefore, for the study of glycosylation patterns on cells, tissue and body fluids are also provided. Information regarding the analysis of glycans, such as the glycosylation patterns on cells, tissues and in body fluids, can be used in diagnostic and treatment methods as well as for facilitating the study of the effects of glycosylation/altered glycosylation on protein function. Such methods are also provided. Methods are also provided to assess protein production processes, to assess the purity of proteins produced, and to select proteins with the desired glycosylation.

Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto MHC molecules. T cells specific for the peptide antigens are activated, leading to an enhanced immune response. The vaccine may comprise antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid encoding antigen(s) linked to a domain that binds at least one receptor. A preferred embodiment of the invention targets HIV-1 env antigen to the CD40 receptor, resulting in delivery of antigen to CD40 positive cells, and selective activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells.

In mobile communication system 100 according to the present invention, mobile station 1 is camped on cell C10 established by base station B10. In the cell C10, there exist indoor cells C11-C13 and outdoor cells C21, C22 as neighboring cells. Mobile station 1 measures received levels of cells C10-C13, C21, C22 and determines cell types of the respective cells, i.e., whether each cell is an indoor cell or not, based on broadcast information M1. Mobile station 1 selects a cell as a reselection target on the basis of the received levels and cell types.

A semiconductor memory device having an error check and correction (ECC) type error recovery circuit in which disposition of ECC cells is improved. The memory device comprises: a memory cell array including a plurality of normal cell array portions and an ECC cell array portion; an X decoder for selecting one of word lines in the memory cell array, the word lines extending from the X decoder to the memory cell array; an ECC operation circuit for performing error check and correction based on cell data read out from a selected word line, the cell data including data from normal cells and ECC cells of the selected word line. The ECC memory cell array portion is disposed at a location other than the far end of the word lines from the X decoder, that is, the ECC cell array portion is disposed at a location in which read out speed of data from ECC cell or cells does not become the worst speed in the memory device. Therefore, the worst data read out speed can be measured from outside.

An integrated circuit (IC) including at least one combinational logic path. The combinational logic path includes two types of logic blocks cells that compensate each other for fabrication parameter effects on cell transistors. The two types may be dense cells with field effect transistor (FET) gates on contacted pitch and isolated cells with FET gates on wider than contacted pitch. Dense cell delay changes from the FET gates being printed out of focus are offset by isolated cell delay changes.

The invention comprises a hand-held device with multiple keys on its face ("face-keys") and with one or more buttons on its side ("side-buttons"). A user types a character (or invokes a function) by pressing one of the face-keys using a finger on the hand that is not holding the device while simultaneously holding in combinations of the side-buttons with fingers on the hand that is holding the device. Pressing a face-key without holding in any of the side-keys produces a given character (or function). Pressing the same face-key while simultaneously holding in a given combination of the side-keys can result in a different character (or function). The invention allows for faster typing of text on cell phone handsets and other hand-held devices.

The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

A process for identifying the presence or absence of target objects inside or outside of cells is disclosed. The target objects are identified by highlighting them and collecting and analyzing image data. When target objects are present, the process can determine their size and/or shape and/or location. With this information, diseases, conditions, syndromes, or stimuli-induced effects may be diagnosed and/or courses of treatment monitored. The process may be used to determine the effect of stimuli on cells and can be used in the fields of medical diagnostics, drug efficacy screening, and drug toxicity screening. For example, after the appropriate test cells have been exposed to a chemical agent and allowed to undergo nuclear division, the micronuclei frequency determined indicates whether the chemical agent is clastogenic and/or aneugenic, which information can be used in a drug discovery program.

In compound screening using cell images, compounds having an effective action on cells are searched for by automated processing, to more perform existing methods for compound searching more effectively. There is provided an apparatus including an image-acquisition unit for capturing a plurality of cell images under different image-acquisition conditions; and an analysis unit for extracting a cell position and at least one feature on the basis of the plurality of cell images and for performing statistical analysis with the extracted features serving as parameters.

The invention provides antibodies to a mutant form of the epidermal growth factor receptor known as EGFRvIII found only or primarily on the surface of glioblastoma cells, and on cells of breast, ovarian and non-small cell lung carcinomas. The antibodies provided by the invention have the complementarity determining regions (“CDRs”) of the scFv designated MR1, but with mutations at positions 98 and 99 in the CDR3 of the heavy chain variable region and, optionally, in other CDRs. In particular, the invention provides an antibody, designated MR1-1, which mutates MR1 in the CDR3 of the VH and VL chains. The invention provides additional antibodies in which MR1 is mutated in the CDR1 and 2 of VH or VL, or both.

A method of reestablishing a RRC connection by the mobile terminal in a RRC_CONNECTED state is disclosed, where the method includes selecting a target cell based on cell quality values measured by using signals from a candidate cell set, determining a cell type of the target cell, and transmitting a RRC connection reestablishment request message to the target cell, when the target cell is a first type cell providing with both a emergency service and a normal service.

Disclosed are systems and methods that allow the a mobile communications device to perform inter-frequency and inter-RAT measurements while receiving MBMS data. As disclosed, control of measurement occasions are decided on by the UE using Discontinuous Reception during Forward Access Channel reception. Using aspects of the disclosed embodiments, each UE individually decides when to perform inter-frequency/RAT measurements (provided performance requirements on cell reselection are met). Outer coding procedures may then be performed to recover data lost during the measurements.

A method for treating a target tissue in a patient in need thereof is provided. The method includes the steps of identifying one or more characteristics of one or more cells of a target tissue; calculating a threshold electric field for inducing IRE in the target tissue based on the one or more characteristics; constructing a treatment protocol of one or more pulse parameters, wherein the treatment protocol is capable of inducing IRE in the target tissue; and delivering the treatment protocol to the target tissue. Systems for treatment planning for medical therapies involving administering electrical treatment energy are also provided.

The present invention includes devices, systems, and methods for assaying cells using cell-substrate impedance monitoring. In one aspect, the invention provides cell-substrate impedance monitoring devices that comprise electrode arrays on a nonconducting substrate, in which each of the arrays has an approximately uniform electrode resistance across the entire array. In another aspect, the invention provides cell-substrate monitoring systems comprising one or more cell-substrate monitoring devices comprising multiple wells each having an electrode array, an impedance analyzer, a device station that connects arrays of individual wells to the impedance analyzer, and software for controlling the device station and impedance analyzer. In another aspect, the invention provides cellular assays that use impedance monitoring to detect changes in cell behavior or state. In some preferred aspects, the assays are designed to investigate the affects of compounds on cells, such as cytotoxicity assays. In other preferred aspects, the assays are designed to investigate the compounds that effect IgE-mediated responses of cells to antigens.